Artelo biosciences to present its new data on art12.11 tablets compared to epidiolex at the imccb-25 conference in bern, switzerland

Solana beach, calif., feb. 11, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on art12.11, a proprietary cocrystal composed of cannabidiol (cbd) and tetramethylpyrazine (tmp), at the international medical cannabis conference (imccb-25) held at the university of bern, switzerland february 13-14, 2025.
ARTL Ratings Summary
ARTL Quant Ranking